Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services
13 11월 2019 - 7:30AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the launch of Personalis’ Cancer Whole
Genome Sequencing which further extends Personalis’ portfolio of
comprehensive cancer genomics services designed to maximize
biological insights from tumor samples.
“This new offering continues our push to provide our customers
genomics solutions that enable deeper insights into patient
responses to oncology therapies,” said John West, CEO of
Personalis. “We are uniquely poised to provide a leading cancer
whole genome sequencing solution which combines Personalis’ deep
technology and experience in analyzing cancer samples for biopharma
oncology clinical trials and the large-scale laboratory and data
systems developed for the VA MVP program, one of the largest whole
genome sequencing programs in the world.”
Earlier this year, Personalis was awarded a new task order under
its contract with the U.S. Department of Veterans Affairs (VA) for
the VA Million Veteran Program (VA MVP). This order brought the
cumulative scale of orders received to date from the VA MVP to over
110,000 human genomes. Since 2013, Personalis has sequenced over
40,000 MVP samples. Personalis anticipates it will sequence the
additional samples over the coming years as they are received from
the VA.
“As our understanding of the complexity of underlying mechanisms
of cancer grows, it is becoming increasingly important to evaluate
genome-wide structural variants, and other forms of non-coding
genetic variation,” commented Dr. Richard Chen, CSO of Personalis.
“This new service advances our position at the leading edge of
cancer translational research with biopharma customers.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT Platform is designed
to adapt to the complex and evolving understanding of cancer,
providing its biopharmaceutical customers with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single tissue sample. Personalis also provides
genomic information to the VA Million Veterans Program as part of
their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112006118/en/
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024